Costs and margins
No data available for this market
BRIEF: For the nine months ended 30 September 2014, Enzon Pharmaceuticals Inc revenues decreased 8% to $24.9M. Net income increased 81% to $23M. Revenues reflect Royalties decrease of 6% to $24.8M, Miscellaneous income decrease of 85% to $93K. Net income reflects General and administrative decrease of 75% to $1.9M (expense), Restructuring charges decrease from $3.8M (expense) to $0K.
* Open a stockbroking account and place your first trade before 31 December 2014 and get commission-free trades on all stocks for one calendar month from the date of your first trade. Does not apply to trades placed over the phone. If your free month expires before 31 December 2014, we'll give you a reduced rate of £6 per trade on UK stocks until the end of the year. Our normal stockbroking charges and fees will apply once the offer period is complete. See full terms and conditions.